Fennec Pharmaceuticals Reports $1.973M Net Income and $17.874M Revenue in Latest Quarter

Fennec Pharmaceuticals Inc. reported significant financial improvements in its latest quarterly filing, showcasing a net income of $1.973 million for the three months ended June 30, 2026, compared to a net loss of $3.152 million in the same period last year. Total revenue for the second quarter reached $17.874 million, a substantial increase from $9.652 million in the prior year, driven primarily by a 77% rise in net product sales of its flagship product, PEDMARK®, which amounted to $17.164 million, up from $9.652 million. For the first half of 2026, the company reported total revenue of $32.982 million, compared to $18.403 million in the first half of 2025, reflecting a 79% year-over-year increase.

The company’s operating expenses also saw notable changes, with total operating expenses rising to $16.137 million in the second quarter of 2026 from $12.384 million in the same quarter of 2025. This increase was largely attributed to heightened selling and marketing expenses, which surged to $10.659 million from $4.784 million, as Fennec expanded its sales force and marketing initiatives to enhance market penetration, particularly among adolescent and young adult patients. Conversely, general and administrative expenses decreased significantly, reflecting reduced legal and professional fees following the conclusion of patent litigation.

Fennec's balance sheet as of June 30, 2026, showed total assets of $75.753 million, up from $70.551 million at the end of 2025. The company reported cash and cash equivalents of $41.249 million, an increase from $36.788 million, indicating improved liquidity. Current liabilities rose to $12.394 million from $10.518 million, primarily due to an increase in contract liabilities. The company’s stockholders’ equity also improved, reaching $42.442 million compared to $35.472 million at the end of the previous fiscal year.

Strategically, Fennec has made significant strides in expanding its market presence. The company entered into a licensing agreement with Norgine Pharma UK Limited, granting Norgine exclusive rights to commercialize PEDMARQSI® in Europe, Australia, and New Zealand. This agreement includes an upfront payment of approximately $43 million and potential milestone payments totaling up to $230 million, along with tiered royalties on net sales. The company is also actively pursuing regulatory registration for PEDMARK® in Japan, following positive results from an independent clinical trial.

Looking ahead, Fennec Pharmaceuticals remains optimistic about its growth trajectory, bolstered by its unique position in the market with PEDMARK® as the only FDA-approved therapy for preventing cisplatin-induced ototoxicity in pediatric patients. The company anticipates continued revenue growth driven by increased market penetration and ongoing efforts to expand its product offerings and geographic reach.